Proton magnetic resonance spectroscopic imaging as a cancer biomarker for pediatric brain tumors (Review).
Magnetic resonance (MR) techniques offer a non-invasive, non-irradiating yet sensitive approach to diagnose and monitor cancer, which encompasses diverse processes affecting various aspects of pathophysiology. Techniques such as MR spectroscopy (MRS) have been developed and applied to monitor the metabolic aspects of cancer. Given that cancer is such a variable disease, biomarkers identified using MRS represent a promising advance and may suggest appropriate therapy, especially when diagnostic biopsies are not feasible. This article will focus on proton MRS, which appears to be the most promising MR method and is complementary to existing diagnostic methods that may be used to characterize and monitor cancer processes. We further focus on applying the MRS technology to pediatric brain tumors, the leading cause of pediatric cancer mortality.
Tzika
A Aria
AA
NMR Surgical Laboratory, Department of Surgery, Massachusetts General Hospital and Shriner's Burn Institute, Harvard Medical School, Boston, MA 02114, USA. atzika@hms.harvard.edu
D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002648:Child; D001330:Electronic Data Processing; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009367:Neoplasm Staging; D011379:Prognosis; D011522:Protons
D014408:Biomarkers, Tumor; D011522:Protons